Ying Miao

Ying Miao

Auto-generated profile, based on publicly available information

Ying Miao

International Institute of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University , Suzhou, Jiangsu, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
HCHuang Chen
Huang Chen
WZWenbo Zhou
Wenbo Zhou
ABAiwu Bian
Aiwu Bian
QZQiansen Zhang
Qiansen Zhang
YMYing Miao
Ying Miao
ZYZhengfang Yi
Zhengfang Yi
Purpose: Pancreatic cancer is the worst prognosis among all human cancers, and novel effective treatments are urgently needed. Signal transducer and activator of transcription 3 (STAT3) has been demonstrated as a promising target for pancreatic cancer. Meanwhile, selectively targeted STAT3 with small molecule remains been challenging. Experimental Design: To specifically identify STAT3 inhibitors, more than 1.3 million compounds were screened by structure-based virtual screening and confirmed with the direct binding assay. The amino acid residues that WB436B bound to were verified by induced-fit molecular docking simulation, RosettaLigand computations, and site-directed mutagenesis. On-target effects of WB436B were examined by microscale thermophoresis, surface plasmon resonance, in vitro kinase assay, RNA sequencing, and selective cell growth inhibition assessment. In vivo studies were performed in four animal models to evaluate effects of WB436B on tumor growth and metastasis. Kaplan–Meier analyses were used to assess survival. Results: WB436B selectively bound to STAT3 over other STAT families protein, and in vitro antitumor activities were improved by 10 to 1,000 fold than the representative STAT3 inhibitors. WB436B selectively inhibits STAT3-Tyr705 phosphorylation, STAT3 target gene expression, and the viability of STAT3-dependent pancreatic cancer cells. WB436B significantly suppresses tumor growth and metastasis in vivo and prolongs survival of tumor-bearing mice. Mechanistic studies showed that WB436B have unique binding sites located in STAT3 Src homology 2 domain. Conclusions: Our work presents the first-in-class selective STAT3 inhibitor WB436B as a potential therapeutic candidate for the treatment of pancreatic cancer.

31 October 2023 in Journal of Virology
Verified
Journal Article
Open access
LZLichao Zang
Lichao Zang
XYXinyu Yang
Xinyu Yang
Yan ChenYan Chen
Yan Chen
FHFan Huang
Fan Huang
YYYukang Yuan
Yukang Yuan
WSWei-Feng Shi
Wei-Feng Shi
The 2A protease (2A pro ) encoded by enterovirus 71 (EV71) serves as an accessory protein with significant involvement in the regulation of EV71 infection and viral replication. EV71-2A pro exhibits the ability to suppress various host factors, thereby disrupting the cellular antiviral immune response. However, whether host factors downregulate EV71-2A pro remains largely unknown. Here, we discovered that the speckle-type POZ protein (SPOP), functioning as a host E3 ubiquitin ligase, triggers ubiquitination modifications and subsequent degradation of EV71-2A pro . SPOP interacts with EV71-2A pro and exhibits a dose-dependent downregulation of EV71-2A pro levels. Conversely, knockdown of endogenous SPOP upregulated EV71-2A pro levels. Subsequent investigations revealed that the SPOP facilitates the lysosome-dependent degradation of EV71-2A pro by inducing K48-linked polyubiquitination of EV71-2A pro , which ultimately restricts EV71 replication. These findings shed light on the ubiquitination and lysosome-dependent regulation of the crucial EV71-encoded protease, offering a potential therapeutic target for the treatment of EV71 infection. IMPORTANCE: EV71 poses a significant health threat to children aged 5 and below. The process of EV71 infection and replication is predominantly influenced by ubiquitination modifications. Our previous findings indicate that EV71 prompts the activation of host deubiquitinating enzymes, thereby impeding the host interferon signaling pathway as a means of evading the immune response. Nevertheless, the precise mechanisms by which the host employs ubiquitination modifications to hinder EV71 infection remain unclear. The present study demonstrated that the nonstructural protein 2A pro , which is encoded by EV71, exhibits ubiquitination and degradation mediated by the host E3 ubiquitin ligase SPOP. In addition, it is the first report, to our knowledge, that SPOP is involved in the host antiviral response.

25 November 2025
Verified
Other
Open access
HCHuang Chen
Huang Chen
WZWenbo Zhou
Wenbo Zhou
ABAiwu Bian
Aiwu Bian
QZQiansen Zhang
Qiansen Zhang
YMYing Miao
Ying Miao
ZYZhengfang Yi
Zhengfang Yi
Table S1. List of antibodies used and their technical information Table S2. The sequence of Real-time PCR primersTable S3. The sequence of shRNAs for silencing STAT3 Table S4. The sequence of ChromatinImmunoprecipitation (Ch-IP) PCRTable S5. The binding affinities of WB436B towards STAT member protein in SPR assay Table S6. Selectivity profiling of WB436B in a kinase panel

1 April 2023
Verified
Other
Open access
HCHuang Chen
Huang Chen
WZWenbo Zhou
Wenbo Zhou
ABAiwu Bian
Aiwu Bian
QZQiansen Zhang
Qiansen Zhang
YMYing Miao
Ying Miao
ZYZhengfang Yi
Zhengfang Yi
Fig. S1. Structure-based ligand discovery of STAT3 inhibitorsFig. S2. Surface plasmon resonance analysis of interactions between WB436B to STATfamily proteinsFig. S3. The biology evaluation of WB436B inactive analogue WB345Fig. S4. The mutation in STAT3 SH2 domain directly inhibited STAT3 transcriptionalactivitiesFig. S5. WB436B induced pancreatic cancer cells apoptosisFig. S6. STAT3 knockdown reduced PDAC cells growth and colony formationFig. S7. WB436B displayed little cytotoxicity to STAT3 stable knockdown PDAC cells.Fig. S8. STAT3 depletion inhibited the growth of PDAC cellsFig. S9. WB436B suppressed STAT3 nuclear translocation and the binding to the targetgenes in pancreatic cancer cellsFig. S10. WB436B was well-tolerated in vivoFig. S11. WB436B was well-tolerated in pancreatic cancer metastatic mouse model.Fig. S12. WB436B inhibited PDAC tumor metastasis in vivoFig. S13. WB436B decreased PDAC tumors angiogenesis, inhibited tumor-associatedmacrophage infiltration and induced apoptosis in vivo

1 April 2023
Verified
Other
Open access
HCHuang Chen
Huang Chen
WZWenbo Zhou
Wenbo Zhou
ABAiwu Bian
Aiwu Bian
QZQiansen Zhang
Qiansen Zhang
YMYing Miao
Ying Miao
ZYZhengfang Yi
Zhengfang Yi
Table S1. List of antibodies used and their technical information Table S2. The sequence of Real-time PCR primersTable S3. The sequence of shRNAs for silencing STAT3 Table S4. The sequence of ChromatinImmunoprecipitation (Ch-IP) PCRTable S5. The binding affinities of WB436B towards STAT member protein in SPR assay Table S6. Selectivity profiling of WB436B in a kinase panel

1 April 2023
Verified
Other
Open access
HCHuang Chen
Huang Chen
WZWenbo Zhou
Wenbo Zhou
ABAiwu Bian
Aiwu Bian
QZQiansen Zhang
Qiansen Zhang
YMYing Miao
Ying Miao
ZYZhengfang Yi
Zhengfang Yi
Table S1. List of antibodies used and their technical information Table S2. The sequence of Real-time PCR primersTable S3. The sequence of shRNAs for silencing STAT3 Table S4. The sequence of ChromatinImmunoprecipitation (Ch-IP) PCRTable S5. The binding affinities of WB436B towards STAT member protein in SPR assay Table S6. Selectivity profiling of WB436B in a kinase panel